<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235039</url>
  </required_header>
  <id_info>
    <org_study_id>VIAject -030J</org_study_id>
    <nct_id>NCT01235039</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biodel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biodel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test for bioequivalence of VIAject®7 and VIAject®25&#xD;
      and to compare the pharmacokinetic/Pharmacodynamic/tolerability characteristics of VIAject®7&#xD;
      with those of VIAject®25 and insulin lispro.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>0-480 minutes</time_frame>
    <description>Area under the serum insulin concentration curve for the time interval 0-480 min (AUC-INS 0-480) and maximum serum insulin concentration (C-INS max) (VIAject®7and VIAject®25 only)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>0-240 minutes</time_frame>
    <description>AUC-INS: area under the serum insulin concentration curve for the time period 0-240 minutes&#xD;
AUC-INS: area under the serum insulin concentration curve for the time period 0 (VIAject® dosing) to the time when the insulin value returns to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose infusion rate</measure>
    <time_frame>Between 0-240 minutes and 0-480 minutes</time_frame>
    <description>•AUCGIR: area under the glucose infusion rate curve for the following time periods: 0-240, 0-480 minutes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIAject®25 for subcutaneous application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIAject®7 for subcutaneous application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Lispro for subcutaneous application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIAject®25</intervention_name>
    <description>Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL</description>
    <arm_group_label>Formulation A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIAject®7</intervention_name>
    <description>One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL</description>
    <arm_group_label>Formulation B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL</description>
    <arm_group_label>Formulation C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥19 to ≤65 years&#xD;
&#xD;
          -  Body Mass Index: ≥18 - ≤28 kg/m2&#xD;
&#xD;
          -  Diagnosed with Type 1 Diabetes Mellitus for at least 1 year&#xD;
&#xD;
          -  Insulin antibody less than or equal to 10 µU/mL at screening&#xD;
&#xD;
          -  Non-smoker, defined as no nicotine consumption for at least one year.&#xD;
&#xD;
          -  Signed and dated informed consent obtained before any trial-related activities.&#xD;
             (Trial-related activities are any procedure that would not have been performed during&#xD;
             normal management of the subject)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  C-peptide value of &gt;1.0 ng/mL&#xD;
&#xD;
          -  HbA1c value of &gt; 10.0%&#xD;
&#xD;
          -  History of hypersensitivity to any of the components in the study medication&#xD;
&#xD;
          -  History of severe or multiple allergies&#xD;
&#xD;
          -  Treatment with any other investigational drug in the last 3 months before study entry&#xD;
&#xD;
          -  Any systemic treatment with drugs known to interfere with glucose metabolism such as&#xD;
             systemic corticoids, non-selective beta-blockers, and monoamine oxidase (MAO)&#xD;
             inhibitors within 3 months prior to randomization.&#xD;
&#xD;
          -  Changes (type of drug or dose) in concomitant medication other than insulin or insulin&#xD;
             analogues in the last 3 weeks prior to randomization.&#xD;
&#xD;
          -  Use of non-prescription drugs, except routine vitamins, within 3 weeks prior to the&#xD;
             first dose of the test drug. Occasional use of paracetamol/acetaminophen is permitted.&#xD;
&#xD;
          -  Progressive disease likely to prove fatal (e.g. malignancies)&#xD;
&#xD;
          -  Current drug or alcohol abuse, or a history of drug or alcohol abuse which in the&#xD;
             opinion of the Investigator will impair subject safety or protocol compliance&#xD;
&#xD;
          -  Significant cardiovascular, respiratory, gastrointestinal, hepatic, renal,&#xD;
             neurological, psychiatric and/or hematological disease as evaluated by the&#xD;
             Investigator&#xD;
&#xD;
          -  Clinically significant abnormal hematology or biochemistry screening tests, as judged&#xD;
             by the Investigator. In particular, subjects with elevated liver enzymes (AST or ALT&#xD;
             &gt;2 times the upper limit of normal) or impaired renal function (serum creatinine&#xD;
             values above the upper limit of normal) will not be allowed to enter the trial.&#xD;
&#xD;
          -  Any serious systemic infectious disease during the four weeks prior to the first dose&#xD;
             of study drug, as judged by the Investigator.&#xD;
&#xD;
          -  History of any illness that, in the opinion of the Investigator, might confound the&#xD;
             results of the trial or pose a risk in administering the trial drug to the subject. In&#xD;
             particular, subjects with significant cardiovascular disease, anemia (hemoglobin below&#xD;
             the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial.&#xD;
&#xD;
          -  Blood donation within the last 30 days&#xD;
&#xD;
          -  A woman who is lactating&#xD;
&#xD;
          -  Pregnant women or women intending to become pregnant during the study&#xD;
&#xD;
          -  A sexually active woman - not using adequate contraceptive methods (adequate&#xD;
             contraceptive measures include: implants, injectables, combined oral contraceptives,&#xD;
             hormonal intrauterine device [IUD], sexual abstinence or vasectomized partner)&#xD;
&#xD;
          -  Positive serology for HIV, Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Abnormal ECG, safety lab or physical examination results that are deemed clinically&#xD;
             significant by the Investigator&#xD;
&#xD;
          -  Lack of compliance or other reasons which, in the opinion of the Investigator, prevent&#xD;
             the participation of the subject in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Heise, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <disposition_first_submitted>July 28, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 28, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 29, 2015</disposition_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

